Patient-Reported Quality of Life and Treatment Experiences Among Patients with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Aflibercept in Colombia: A Qualitative Study Authors: Maria Adelaida Piedrahita, Wanderley Augusto Arias-Ortiz, Claudia Patricia Acosta Cadavid, Eduardo Cadena Galvis, Fernando Yaacov Peña Published: 2026 ABSTRACT AbstractPurposeTo explore the experiences and perceptions of patients with neovascular age-related macular degeneration (AMD) receiving anti-VEGF therapy and understand how treatment influences their quality of life.Patients and MethodsA qualitative study informed by a phenomenological perspective and employing a hybrid deductive–inductive thematic analysis was conducted at an ophthalmologic center in Medellín, Colombia. Fourteen patients with confirmed AMD undergoing intravitreal aflibercept treatment participated in semi-structured telephone interviews. Participants were selected through purposive sampling until meaning saturation was achieved, defined as the point at which no new experiential themes emerged. Interviews were transcribed verbatim and analyzed using a hybrid deductive–inductive thematic analysis guided by the Felce and Perry quality-of-life framework, supported by ATLAS.ti v24.ResultsPatients described AMD as a condition strongly associated with fear, uncertainty, and emotional distress, particularly related to progressive visual loss and blindness. Intravitreal injections were initially perceived as invasive and anxiety-provoking; however, over time many participants associated treatment with hope, visual stability, and preservation of independence. Family support, religious beliefs, and trust in the treating ophthalmologist emerged as important factors for emotional coping and treatment adherence. Participants also reported subjective improvement in daily activities such as reading, mobility, self-care, and social interaction. Nevertheless, some continued to experience limitations related to transportation, dependence on others, and social isolation. Concerns about continuity of care and access to medication were frequently expressed.ConclusionQuality of life in patients with AMD receiving anti-VEGF therapy extends beyond visual outcomes alone and is deeply influenced by emotional, social, and functional factors. Although treatment generated fear and discomfort at the beginning, it also represented an opportunity to maintain autonomy and social participation. These findings highlight the importance of patient-centered care strategies that integrate psychosocial support, clear communication, and continuous access to treatment.Keywords: intravitreal injections, vision disorders, activities of daily living, medication adherence Introduction Age-Related Macular Degeneration (AMD) is a degenerative, multifactor condition that mainly affects patients over 60, and entails the gradual loss of central vision, and along with glaucoma and diabetic retinopathy, it is one of the main causes of irreversible visual impairment.1–4 Its neovascular form presents the most aggressive evolution: choroidal neovascularization resulting from “vascular endothelial growth factor” (VEGF), which produces exudation, hemorrhages and subretinal scarring and rapid decline in visual acuity.2,3 Even though AMD presents with dry and neovascular phenotypes,5,6 it is the latter which requires specific treatment with anti-VEGF therapy via intravitreal injections, the main purpose of which is to contain its evolution and protect sight.1,7 The treatment plan and the number of injections per year depend on the regime set by the doctor. It begins with monthly administrations, which then progress to bimonthly administrations with the possibility of stretching the period to three months in certain patients, all of this under strict follow-up allowing to timely detect clinical changes.8–10 This individualized approach is essential, considering that VEGF is key in the physiopathology of neovascular AMD, as it fosters angiogenesis and increases vascular permeability.10 Despite the fact that anti-VEGF has proven its effectiveness both in anatomical and functional terms, it brings with it a major physical, emotional and economic strain. This is mainly due to the procedure’s invasive and repeated requirement and the pain and discomfort caused by the intravitreal injections. Furthermore, anticipatory anxiety, the uncertainty as to the evolution and therapy fatigue have been linked to lower adherence, even in the cases in which a few patients have reported partial improvement of their vision.11,12 A recent systematic review and network meta-analysis comparing the currently available anti-VEGF agents for neovascular AMD further supports the central role of these therapies in stabilizing or improving visual outcomes, while emphasizing that differences among agents relate primarily to their efficacy–safety profile and durability rather than to their overall therapeutic benefit. Although aflibercept demonstrated one of the most favorable efficacy–safety balances, the authors highlighted that long-term treatment burden and the need for repeated intravitreal injections remain common challenges across all anti-VEGF therapies, underscoring the importance of considering patients’ experiences and treatment adherence alongside clinical outcomes.13 In addition, recent advances in artificial intelligence using multimodal retinal imaging have shown promising results for predicting disease progression and treatment response, supporting more individualized monitoring strategies. Although these technologies cannot replace patients’ perceptions of their quality of life, they may complement patient-reported experiences by providing objective imaging-based information to guide treatment decisions and optimize follow-up, reinforcing the value of integrating clinical, imaging, and patient-centered outcomes in the management of neovascular AMD.14 The evidence available on the pathology and the alternatives for its treatment have mostly centered on visual acuity results and imaging biomarkers, while psychosocial outcomes and patient reported experiences tend to be overlooked.15,16 In this case, the quality of life (QoL) concept and the derivations applied to the context of health, such as Health-Related QoL come to the forefront. Considering the foregoing, instruments have been created to measure Health-Related QoL in ophthalmology, and specifically in patients with retinal diseases.17–19 However, instruments developed for other sociocultural contexts have been used, which restricts their application in Latin-American populations.19 It became clear that the healthcare dynamic in these populations is complex and that it was also vital to study their QoL. To this end, qualitative studies which allowed thoroughly exploring and in their own terms the subjective aspects of the treatment were prepared, providing a more holistic analysis which no longer centered on measurable results. In addition to the above, population aging must be taken into account, as it is estimated that the number of people exposed to these treatments will increase: by 2030, one in 6 people will be over the age of 60, and by 2050, this figure exceeds 2.1 billion worldwide.20 In middle-income countries such as Colombia, access barriers, late diagnosis and socioeconomic and cultural inequalities may exacerbate the disease’s burden, condition adherence and have a greater impact on QoL.5,21 This is why assessing QoL as defined by the WHO from a functionality and ability to carry out everyday activities perspective becomes even more important when it comes to AMD, as a decline in central vision directly impacts autonomy, social roles and emotional wellbeing.7,22 In the context of population aging, age-related macular degeneration has become increasingly problematic, especially in middle-income countries such as Colombia where access barriers, late diagnosis and social inequalities may increase their impact. The loss of central vision does not only affect functionality, but also autonomy, social roles and emotional wellbeing, thus becoming a key factor in QoL. In this context, this study will provide a qualitative exploration of the personal perception and experiences of AMD patients treated with anti-VEGF. Materials and Methods This is a qualitative research paper informed by a phenomenological perspective and employing a hybrid deductive–inductive thematic analysis centered on exploring the personal perception and experiences of patients diagnosed with neovascular age-related macular degeneration (AMD) and treated with anti-VEGF, with the purpose of understanding its impact on their QoL.23,24 From a phenomenological perspective, this study sought to understand the meanings that patients attributed to their treatment and its emotional, functional, and social implications. Semi-structured interviews were conducted over the phone in order to facilitate the participation of older adults, making sure they were at ease throughout the interview. The study took place in an ophthalmological institute in Medellin with the participation of patients currently being treated with aflibercept, pursuant to the clinical protocol established. All of the participants signed beforehand an informed consent, which was read and explained during the consult by the attending ophthalmologist. Once the patients confirmed that they understood and accepted the document, they were contacted over the phone for the interview. The protocol was approved by the Institutional Ethics Committee of Universidad El Bosque (CIE 2025-018), following the principles of the Declaration of Helsinki, ensuring the confidentiality and autonomy of and respect for the participants. The target population consisted of patients with a diagnosis of neovascular AMD confirmed by imaging who were receiving intravitreal aflibercept injections at the same institute. Criterion-based purposive sampling was used to select participants who met the eligibility criteria and could provide rich and relevant information regarding their treatment experiences. The final sample included fourteen participants, with recruitment continuing until meaning saturation was achieved, defined as the point at which additional interviews no longer generated new experiential themes or meaningful information relevant to the analysis, as described by Saunders et al25 and Hennink.26 As reference, the limit size between nine and seventeen interviews was used in accordance with the results of previous studies.27 The inclusion criteria were the following: diagnosis of neovascular AMD confirmed by a retina specialist using optical coherence tomography (OCT); patients between 60 and 90 years of age; having received at least the three initial loading doses of intravitreal aflibercept; and being under active treatment at the time of the study. Patients with serious ocular diseases unrelated to AMD, those receiving concomitant ophthalmic treatments, significant cognitive impairment, or communication barriers that could prevent participation in the interview were excluded. Information was collected by following a semi-structured interview script, which took into account the multifunctional approach to QoL proposed by Felce and Perry.28 The initial wellbeing dimensions explored included emotional, material, physical, personal development, self-determination, rights, social inclusion, and interpersonal relationships. These dimensions were selected because they provide a comprehensive framework for exploring the experiences of patients receiving anti-VEGF therapy, encompassing not only the clinical consequences of the disease but also its psychosocial impact, autonomy, and interaction with the surrounding environment. These predefined dimensions served as the initial deductive coding framework while allowing additional categories to emerge inductively from participants’ narratives. Data were collected through semi-structured telephone interviews conducted by two researchers to facilitate the participation of older adults while ensuring consistency across interviews. Interviewer 1 was a fourth-year ophthalmology resident with formal training in clinical research and epidemiology. Interviewer 2 was an associate researcher holding a Master’s degree in Epidemiology and a PhD candidate in Social Sciences, Policy, and Public Health, with experience in qualitative and social science research. Both interviewers had completed certified training in Human Subjects Research and biomedical research ethics. Neither interviewer had any prior professional or personal relationship with the participants before recruitment or data collection. Interviews lasted approximately 25–45 minutes and were audio-recorded with participants’ permission. Although the interview guide was designed to explore all proposed wellbeing dimensions, not all dimensions emerged in the participants’ narratives. This reflects the qualitative nature of the study and the specific context of neovascular AMD and its treatment, where participants naturally emphasized those aspects that they considered most relevant to their visual experience and daily lives. All interviews were recorded, transcribed, and analyzed using ATLAS.ti software version 24 (ATLAS.ti Scientific Software Development GmbH, Berlin, Germany). Data were analyzed using a hybrid deductive–inductive thematic analysis, informed by the phenomenological perspective and guided by Roulston’s proposal.29 Initially, transcripts were read repeatedly to identify meaning units. Preliminary codes were generated using the Felce and Perry28 QoL dimensions as a deductive framework while allowing new codes to emerge inductively from participants’ narratives. Codes were subsequently grouped into conceptual categories, refined into overarching themes based on recurring patterns, and interpreted to understand participants lived experiences. Coding and theme development were reviewed independently by more than one researcher to enhance the credibility of the analysis through analytical triangulation. During the analysis, the language and the expressions used by the participants were included in order to truly convey their experiences vis-à-vis neovascular AMD and the treatment with intravitreal injections. The interpretation focused on understanding the experiences linked to physical pain, fear of losing sight, anxiety in anticipation of the intravitreal injections, the functional impact on their everyday life, and the personal strategies for coping with the treatment. This phase took place ensuring compliance with the ethical research principles, which were approved by the Ethics Committee of Universidad El Bosque, under project code CIE 2025–018, Participant quotations were translated from Spanish into English by a professional medical English translator and subsequently reviewed by the authors to ensure that the original meaning and tone were preserved. Results Fourteen Patients Diagnosed with Neovascular AMD residing in Medellín, Colombia, were interviewed. Criterion based purposive sampling was used to select participants who met the eligibility criteria and could provide rich and relevant information regarding their treatment experiences. Seventeen eligible patients attending a routine aflibercept treatment clinic were invited to participate, all of whom provided written informed consent and agreed to a subsequent telephone interview. Fourteen participants completed the interview, while three could not be reached despite repeated contact attempts. During data analysis, no new experiential themes emerged, indicating that meaning saturation had been achieved. This final sample was consistent with previous qualitative studies, as described above. The average age was 73.9 ± 7.0 years (range: 62–85), with an equitable distribution by sex (50% women). Most of the participants were married or in a domestic partnership (64.3%) and were classified as middle-income socioeconomic strata (Table 1). Table 1Sociodemographic and Clinical Characteristics of the Participants with Neovascular AMDVariableCategoryn (%)/Mean ± SDSexFemale7 (50.0)Male7 (50.0)Age (years)Mean ± SD73.9 ± 7.0Range62–85Marital statusMarried/Cohabiting9 (64.3)Single3 (21.4)Divorced2 (14.3)Education levelPrimary3 (21.4)Secondary6 (42.9)Technical2 (14.3)Undergraduate3 (21.4)Employment statusRetired12 (85.7)Homemaker1 (7.1)Self-employed1 (7.1)Living arrangementLiving alone1 (7.1)Living with others13 (92.9)Socioeconomic status*11 (7.1)22 (14.3)34 (28.6)44 (28.6)53 (21.4)Eye(s) under treatmentOne eye11 (78.6)Both eyes3 (21.4)Disease duration (years)Mean ± SD1.64 ± 1.11Range0.4–4.0Number of intravitreal aflibercept injectionsMean ± SD8.9 ± 3.8Range3–15Notes: *In Colombia, socioeconomic strata are a government-defined residential classification system ranging from 1 (lowest socioeconomic level) to 6 (highest socioeconomic level). In the present study, participants belonged to strata 1–5; therefore, higher stratum numbers indicate higher socioeconomic status.Abbreviation: SD, standard deviation. Sociodemographic and Clinical Characteristics of the Participants with Neovascular AMD Notes: *In Colombia, socioeconomic strata are a government-defined residential classification system ranging from 1 (lowest socioeconomic level) to 6 (highest socioeconomic level). In the present study, participants belonged to strata 1–5; therefore, higher stratum numbers indicate higher socioeconomic status. Abbreviation: SD, standard deviation. From a clinical perspective, 11 participants (78.6%) were being treated with intravitreal injections in one eye, and three (21.4%) in both eyes. The average time of evolution of the disease was 1.64 ± 1.11 years in a 0.4-to-4-year range. Regarding the intravitreal injection treatment, the participants had received between 3 and 15 injections, averaging 8.9 ± 3.8 doses. The variability in time of evolution and number of applications helped gather different experiences vis-à-vis the treatment, reflecting different adaptation phases, expectations and perceptions on the disease’s impact on their QoL. Emotional Wellbeing Emotional wellbeing emerged as a central theme that influenced participants’ perceptions of the disease, their expectations regarding treatment, and their ability to adapt to vision loss. The fear they manifested was based on the disease’s progression and the decrease in visual acuity, along with the fear of ending up blind. Furthermore, when they were diagnosed and explained therapeutic options with intraocular injections, for most of them it was painful and difficult to come to terms with. They also mentioned that this option was discouraging and stressful, as they expected that their eye condition could improve with simpler solutions, such as changing reading glasses or eye drops. Although fear remained present throughout treatment, many participants described a gradual transition from uncertainty to hope, particularly when they perceived visual stability or improvement. Despite the difficulty faced initially relating to the need for intravitreal injections, some of them mentioned having hope of recovering their sight or that the impairment would stop; this boosted their faith and peace of mind, which enabled them to trust in the treatment and helped changing future negative thoughts. When approaching the emotional component, the patients narrated how they came up with strategies to boost resilience throughout the treatment, which was pivotal in order to face the perceived challenges that came with this disease, the reality of a potential result and the trauma caused by an invasive treatment. Family support emerged as an important facilitator of treatment adherence by providing both emotional reassurance and practical assistance, such as transportation and accompaniment to medical appointments. For participants with limited family support, religious beliefs became an alternative coping strategy that helped reduce emotional distress. One participant told us that faith in their religion grew, as they did not have the support of their family because they were in a nursing home. Others also pointed out that when results were not as good as expected, they would be deeply concerned. This discouraged them from keeping up with the antiangiogenic therapy. Up until the time of the interview none of the patients had considered suspending treatment out of fear that they could have relapses or their symptoms worsened. Fear, distress and anxiety due to their disease were permanent, as the patients were afraid that the injections would not help as much as they expected, and they could lose their sight (Table 2). Table 2Voices of the Patients on Emotional WellbeingDimensionPatients’ QuotesFear of the disease“I took the medical tests, and they confirmed the diagnosis of the disease. I was afraid of losing my sight”. (E2)“When I learned that I had this disease I cried and was distressed over what could happen”. (E1)“This frightens me; there are even times when I’m afraid of falling asleep and waking up blind”. (E9)“I am fearful, but more because of the healthcare situation in Colombia. It concerns me that at any point I may no longer receive my medication, and I’ll be forced to pay it out of my own pocket. That really concerns me”. (E14)Improvement expectations“Have no fear and keep the faith that the treatment will save my sight”. (E1)“I had many expectations for the treatment; I thought the results would be better. I had a little faith, but it has not turned out like I expected. I hope I will keep getting better, even though the progress has been slow”. (E5)“I am not distressed; I am reassured because I know that the treatment works and is helping me. I have to be optimistic”. (E4)“I think progress is slow, but that drives me forward and helps me trust that I will be able to maintain my independence”. (E6)“I hope my vision will improve a little more, so I can see clearly with my glasses, especially in the left eye. Keep my independence and not lose entirely the ability to recognize people”. (E2)“I hope I’ll keep getting better and recover my visual independence as much as possible. I hope that my sight will improve and the treatment will allow me to continue being active and participate in things I like, so I won’t feel that restricted”. (E4)“I would like to see better with both eyes and keep stable. I’m not asking for miracles; I only wish to keep what I have and improve a little. The disease is no longer advancing, and I even feel like my sight has improved. This gives me the confidence to keep going”. (E13)Reactions to the injection treatment“It was a blow because you never expect to receive news like this. The idea of receiving injections directly in my eye was terrible, I was scared”. (E8)“Having eye injections makes me uncomfortable; I feel sad when I think of losing my eye and not being able to see again”. (E3)“I wear sunglasses, lower my head, pray along the way, and at home I play music to feel at ease. I learned to cope with it”. (E2)Accompaniment/support as the cornerstone of the treatment“The help given by my wife, my daughters, and even of a niece, has been crucial. They take me to the appointments, they take care of me and assist me when I need it. That closeness makes me feel safe and not as worried because I know I am not facing this alone”. (E12)“My husband and my sister go with me whenever they can and that encourages me”. (E9)“My partner has been my rock throughout this process. Without him I wouldn’t have been able to face the disease or the treatment. My sister, who lives across the street from me, has also been helping me. Knowing that they are there makes me feel safe and cared for. If it weren’t for them, I would feel helpless”. (E13)“The permanent company of my wife, who is younger than I am, and of my children has been vital. Their constant presence encourages me and makes my recovery a lot lighter. You feel like you have a team on your side”. (E14)“Having the doctors explain patiently the situation to me and my family was also key, because that support helps reduce fears and makes you feel safe”. (E9)“My family does not live with me, so they are not present. I give them updates but they are not here. Sometimes I feel like I’m facing this alone”. (E8)Role of the attending doctor“I’ve felt well and at ease. I’m even happy to have chosen the right doctor”. (E1)“She gave me hope because I finally understood what was happening and that it could be treated”. (E4)“Regarding the injections, I face them courageously. Even though I am afraid of getting poked, the process has been easy thanks to the doctor: she knows me, knows that I’m nervous and stays with me”. (E1)“I’ve felt accompanied. The important thing is that the doctors explain properly how it all will go, because at first it is really scary. And then they must also be caring, because that is reassuring”. (E2)Note: E: interviewee. Voices of the Patients on Emotional Wellbeing Note: E: interviewee. In the cases in which participants perceived an improvement in their vision, they described increased hope regarding the possibility of preserving their sight with intravitreal injections. Perceived visual improvement was closely linked to increased hope, confidence, and the preservation of independence. Most of them reported feeling better and perceived improvements in their vision, describing that they were able to recognize faces, read, sew, play cards with friends, and attend church. Trust in the treating ophthalmologist emerged as a key factor linking emotional wellbeing with treatment adherence. Anxiety, distress and fear of intravitreal injections were always present, especially at first. However, many patients would focus their expectations on their interaction with the healthcare professionals. For some, the accompaniment and education in the treatment and the friendly treatment of the medical team helped reduce uncertainty and build trust. Physical and Material Wellbeing Physical and material wellbeing were closely related to participants’ perceived ability to maintain independence and continue their usual daily activities. As for physical wellbeing, the patients perceived that the treatment had a positive impact, which they associated with recovering functional abilities and resuming day-to-day activities. Overall, no major restrictions to their routines were mentioned. Participants reported remaining autonomous in their personal care and household activities, and described feeling more confident in their surroundings after initiating treatment. Several participants stated that from the moment they started receiving the injections they were able to carry out activities that were difficult before, such as buying groceries at the store, taking charge of their own care and hygiene, and engaging in household chores, such as cooking and cleaning (Table 3). Table 3Voices of the Patients Regarding Physical and Material WellbeingDimensionPatients’ QuotesPhysical wellbeing“Transportation has been affected to most because I cannot see well, and moving around on my own is difficult”. (E5)“I’ve lost most of my independence. Before, I used to do crossword puzzles and make handicrafts that I would then sell at fairs. That kept me active and energetic. I cannot do those things with ease anymore and I greatly miss them”. (E13)“At first, I was limited in almost every way. I felt blind and clumsy”. (E14)Material wellbeing“Now I can buy and sell with more confidence at the street market. Before, it used to be more difficult”. (E10)“I used to take on small construction works to contribute to the household, but now that I’ve lost my sight I cannot do it anymore. It makes me feel like a burden”. (E12)“My anxiety is not so much about the treatment, but about who is going to take me to the appointments and whether we have enough money to pay for transportation”. (E12)“Thanks to the treatment my sight has improved. That gives me confidence to keep on working and supporting my family”. (E10)“Sometimes we do not have money for a taxi, and one time we arrived late and I missed the appointment”. (E3)Note: E: interviewee. Voices of the Patients Regarding Physical and Material Wellbeing Note: E: interviewee. However, certain patients pointed out that they did not perceive a significant improvement with the treatment or certain limitations still remained. These difficulties related especially to leaving the house, indicating problems with transportation and mobility in outside areas. In this context although some mentioned a subjective improvement to their eyesight, they also described the loss of or limitations to their ability to be independent regarding activities they used to carry out before with confidence. In certain cases, this made them feel like they had become a burden to their families. Those who were no longer working reported major changes in this aspect, while those who were still active workers indicated that the treatment gave them the confidence to continue working. As for their material wellbeing, the patients mentioned that for them this was linked to their ability to take care of their basic needs in a stable and sustainable manner, thus allowing them to live a dignified life. In general, they stated that financial hardship was negligible as they were living a vital phase related to retirement or old age, and their eye condition did not directly affect their income. In this sense they sustained that they had not suffered major economic difficulties. However, the treatment did constitute an additional economic burden due to their out-of-pocket expenses linked to coming from and going to the appointments to receive the injection, or the costs related to the treatment per se, items which were not always included in their budget, and sometimes forced them to turn to their family for help. The patients who were head of household and continued being the financial providers of their family, observed decreased income and manifested that they were unable to keep on running their business or producing resources due to their diminished eyesight. Some of them even stated that they had become a burden to their family. These financial difficulties disturbed the family group dynamics, which in turn led to other problems linked to the decreasing QoL of all the members and caretakers. A significant finding was that some participants reported regaining sufficient confidence to continue working, which they attributed to the treatment and their perceived improvement in vision. They associated this with an improved QoL for themselves and their families, owing to the income generated through their work. Autonomy and Self-Determination The interviews with the patients show how diminished visual acuity limits their ability to tackle everyday activities and their personal development, thus significantly affecting their autonomy, their QoL and the possibility of interacting with the world around them. Considering the foregoing, the patients interviewed reported reduced autonomy to engage in activities such as leaving the house, crossing roads or using public transportation, all of which in turn made them feel insecure (Table 4). Table 4Voices of the Patients Regarding Self-Determination and AutonomyDimensionPatients’ QuotesSelf-determination“I have a hard time seeing the cards when I play board games”. (E3)“I can no longer read like I used to”. (E9)“Many things I used to be able to do easily now require help. For example, leaving the house alone is not the same; I feel insecure and have to rely on others. I do not want to inconvenience others, and it makes me sad because I truly enjoyed my independence”. (E4)“I haven’t had any great limitations; I am still autonomous in my self-care”. (E13)Autonomy“I can see the ground better when I walk; I’m not as fearful of falling now as I was before”. (E3)“I go out less because my blurry vision affects me. I prefer to avoid situations that represent any risk, especially concerning safety”. (E5)“I hope my sight gets a little better so I will be able to see with my glasses, especially in my left eye. To be able to continue being independent and not lose entirely the ability to recognize people”. (E2)Note: E: interviewee. Voices of the Patients Regarding Self-Determination and Autonomy Note: E: interviewee. Some patients stated that their disease made them learn to be more careful when interacting outside of home since they became more aware of their sight limitations. As the treatment progressed, the patients mentioned that sometimes they were able to resume their hobbies and pastimes thanks to their perceived sight improvement, which enabled them to become a part of their family and social circle once again. On the other hand, other patients perceived a decline in social activities, reporting difficulties relating to getting transportation on their own and engage in recreational activities, setting aside the hobbies or pastimes they used to have. In other interviews they reported not having any difficulties in their personal life, indicating that they hadn’t suffered significant changes to their autonomy. Others mentioned that sometimes they felt more confident carrying out their day-to-day activities at the beginning of their treatment with the intravitreal injections. This phenomenon exposed that the context’s conditions, family support and interaction activities were pivotal to their personal development and how they faced their disease, even before the treatment. In a few interviews, participants explained that despite receiving intravitreal injections, the disease continued to limit their autonomy in everyday activities, and their perceived improvement in vision was insufficient for them to perform daily tasks without assistance. Other patients stated that although they had been informed during their appointments that their disease had shown clinical improvement, including better visual acuity, this improvement was not always reflected in their own perception of vision. Nevertheless, a few patients were grateful to their doctor for their perceived sight recovery and the autonomy gained thanks to the treatment. This in turn fostered adhering to the treatment, leading to more self-confidence, self-sufficiency and the subsequent improved QoL. Patient Rights and Social Inclusion Concerning patients’ rights, most of the interviewees declared having access to healthcare without any issues, for they were covered by their health insurance. These patients said that they were given timely, efficient and good quality care. In spite of the foregoing, some of them did not have the same perception and mentioned difficulties getting access to or starting their treatment. In this sense, they mentioned that they had received decent care and respectful treatment from the medical personnel and the health center in general, along with clear, comprehensive, sufficient and timely information regarding their health, diagnosis, treatments and risks. Only one patient reported not having received sufficient information on the treatment and its side effects. In spite of their compromised sight, the patients stated that they felt welcomed and well treated throughout their entire process, and all of them were able to gain access to the proper management of their condition, highlighting that the institute where treatment was administered presented no inconvenience, as they were contacted to set their appointments and follow-ups, and inquiring as to their evolution after the procedure. As for their right to health, they revealed some misgivings they had related to the decline of the healthcare system nationwide. They were afraid that there would come a time in which they would no longer have access to the medication and would be forced to pay out of their pocket entirely, or worse, that the medication would be out of stock and impossible to get. Regarding the context of social inclusion, not only did the patients manifest the importance of family. For some of them living alone, their neighbors played a relevant role supporting them, as they were members of their community and participated in the social activities of their neighborhood. This reinforced the importance of coming together and the creation of community networks, along with the strengthening of the patients’ socialization strategies (Table 5). Table 5Voices of the Patients Regarding Patients’ Rights and Social InclusionDimensionPatients’ QuotesPatients’ rights“I went to the doctor with my husband, and she explained very patiently what was happening to me with this macular degeneration”. (E4)“I haven’t had any difficulties, thank God. Everything has occurred seamlessly, which reassures me because I know I haven’t interrupted the process. I really have nothing negative to say. On the contrary, I’ve always been treated well and with patience. I am grateful for the care received”. (E4)“I think the side effects should be better explained. Sometimes you do not know what to expect and end up associating them to other conditions, such as colds or malaise”. (E9)“It has been more or less difficult to access treatment. You do what you need to set up the appointments and follow the treatment”. (E6)“Thankfully, it has been easy. They call me, they set the appointments and I feel like they are following up. That reassures me”. (E2)“That’s my greatest fear: that the treatment may be interrupted”. (E13)Social inclusion“I like playing cards but sometimes it saddens me that I cannot see faces clearly. I also dislike staying out late because at night my sight is worse. Even so, I try not to lose contact with my friends”. (E2)“What most affects me is that I do not like going out at night, and because of that I miss meetings or gatherings with friends. Sometimes it makes me sad to not be able to share as much as before, but I cannot see well at night. My sight has diminished a lot”. (E4)“I have trouble identifying people and that makes it difficult to talk to someone or when I meet them on the street. I’m not going to lie, sometimes I isolate myself”. (E5)“Yes, I can no longer go with my partner to the bar every night, nor do I go out partying as before. This saddens me because those were happy moments we used to share before”. (E13)“Most of the time I just do not feel like going out. I’d rather stay at home”. (E14)“That emotional support, that company, have meant a lot to me throughout this process, especially when they go with me to my appointments”. (E4)“My family has not supported me like I thought they would. That hurt, because you think that family would get closer when you’re sick, but it’s not always like that”. (E13)“It is also essential that the doctors take the time to explain the situation to you and your family, because that support helps keeping fear at bay and enables you to feel more confident”. (E9)Note: E: interviewee. Voices of the Patients Regarding Patients’ Rights and Social Inclusion Note: E: interviewee. These community relationships contributed to emotional wellbeing and reduced feelings of isolation. This aspect was perceived as pivotal to avoid the patients’ isolation, as they were happy to meet with others and be accepted despite their disease. They also indicated that it was more difficult to go out, especially at night, when their vision was more affected by the darkness. Some of them stated that they were unable to be with their friends because it was impossible for them to make the trip to get to gatherings, or because they didn’t want to be seen with their disease. This would lead to isolation and sadness in not being able to partake with their friends. On a few occasions, they preferred being alone and homebound. Overall, the findings demonstrate that emotional wellbeing, functional independence, social support, healthcare access, and treatment adherence were closely interconnected. Participants who perceived greater support from family and healthcare professionals reported greater confidence in treatment, while perceived visual stability facilitated autonomy, social participation, and adherence despite the ongoing burden of intravitreal therapy. Discussion Over the last decades the concept of QoL has emerged as an essential component when evaluating people’s health. In this context, this paper provides insight as to patients’ QoL when treated with intravitreal injections for neovascular AMD, understood as a multifactor pathology conditioned by social, family, economic and cultural dimensions and by the health of each patient.30 This approach brings to light the importance of incorporating a quality-of-life assessment in chronic eye pathologies, in addition to the isolated anatomical and functional developments.24–36 The emotional responses described by participants suggest that neovascular AMD is experienced not only as a threat to vision but also as a threat to personal autonomy, identity, and future independence. This may explain why fear remained prominent even after treatment initiation, despite participants reporting perceived benefits of therapy. Thinggaard et al36 in a survey-based cross-sectional study among neovascular AMD patients treated with anti-VEGF, it was evidenced that the improvement of visual acuity and the perceived effectiveness of the treatment was linked to a better QoL, since the stabilization of visual acuity did not only impact clinical parameters, but also resulted in a more favorable perception of QoL. Our findings complement these observations by showing that participants’ emotional responses were closely linked not only to perceived changes in vision but also to their expectations regarding future visual function and independence. While conducting the study we were able to identify that the patients’ everyday activities became the main reflection of the neovascular AMD functional impacts. The difficulty of doing things like reading, moving around, cooking or handling personal issues became one of the main consequences of their visual impairment. However, the results obtained after the treatment with intravitreal injections allowed them to optimize their perceived functional independence. This matched the result of visual rehabilitation models, which highlighted functionality as the core of QoL, as Lamoureux et al37 proved that the impact of vision impairment was mainly reflected on the restriction to carry out day-to-day activities and social participation, which were the core dimensions evaluated with the implemented questionnaire. Together, these findings suggest that patients primarily evaluate their QoL through their ability to maintain meaningful everyday activities rather than through clinical measures alone.37,38 Regarding the evolution of the disease, the study prepared by Thoms et al39 described how the initial visual changes manifested in the impairment of central vision, difficulty to read and recognize faces, distortion of straight lines and the appearance of blurry or no vision areas, which may be explained by the alteration occurring in the macula as the best vision point. In the context of this paper, it is likely that these initial symptoms directly affected the patients’ autonomy and social activities.6,13,19 Although there is no cure for AMD, early diagnosis and timely treatment allow stopping its progress and improving QoL. In this sense, anti-VEGF therapy has transformed the prognosis by helping control the diseases and reduce vision loss.40–43 Within this context, participants perceived treatment as an opportunity to maintain their independence, particularly when supported by a trusting relationship with their ophthalmologist. In Colombia, where repeated access to specialist care and intravitreal treatment depends on continuity within the healthcare system, maintaining this therapeutic relationship may be especially important for sustaining long-term adherence and confidence in treatment. Some patients perceived the treatment with intravitreal injections as painful and fear-inducing, with limited improvement expectations. Still, the possibility of keeping their sight favored their adaptation and fostered resilience. Throughout the process, the assistance of family was vital to their adherence; in other cases, their religious beliefs helped them face the disease. Likewise, the doctor-patient relation became the core of the situation, where communication, trust and education facilitated accepting the treatment, in line with the paper authored by Haskard and DiMatteo,44 which mentioned that there is a significant relation between the way in which the doctor communicates and the patient adheres to treatment. In this sense, communication was not only about conveying information, but also about instilling trust, fostering the patients’ participation and taking down barriers vis-à-vis the treatment. Furthermore, the study’s outcome also exposed that the patients’ beliefs and perceptions regarding their disease directly influenced their therapeutic behavior. The Friedman et al45 study, which combined patient interviews with the clinical assessment of glaucoma patients’ adherence to treatment, points out that ignorance as to the consequences of a diseases, especially loss of sight, as well as the manner in which they are informed, are linked to treatment adherence. Beyond the simple conveyance of information, these findings suggest that the way in which patients understand and re-signify the disease directly influenced their commitment to the treatment. In our population, understanding the disease’s process, the importance of treatment, medical advice, along with social support, are elements that are essential to adherence. This allows stating that the patients’ experience is not restricted to the clinical evolution of the disease, but is built with the proper support received and their social context. The variability in the experiences reported by our participants also suggests that the perceived benefits of anti-VEGF therapy may differ among individuals. While emotional, social and contextual factors likely shape these perceptions, recent evidence indicates that biological factors may also contribute to treatment variability. A recent systematic review demonstrated that genetic polymorphisms, particularly in the CFH and ARMS2 genes, are associated not only with AMD susceptibility but also with differences in anti-VEGF treatment response, supporting the concept that patients may experience distinct therapeutic outcomes despite receiving similar treatment regimens.46 Furthermore, advances in artificial intelligence using multimodal retinal imaging have shown promising results for predicting AMD progression and treatment response, providing objective imaging-based information that may complement, rather than replace, patients’ perceptions of their quality of life. Together, these findings reinforce the importance of an individualized approach that integrates patient-reported experiences with clinical, imaging, and emerging precision-medicine tools to optimize the management of neovascular AMD.47 As for the physical wellbeing aspect, the treatment favored the recovery of functional abilities, enabling most of the patients to maintain their autonomy in everyday activities, instilling confidence in their surroundings, although a few continued to have restricted movement that led to depending on their family. As for material wellbeing, most of the patients did not report a significant economic impact, as they are retired. However, the treatment caused additional expenses which in most cases required the family’s aid. This situation was even more critical in patients who were still working, since they produced less income and a greater financial burden. Nevertheless, some of them managed to return to their work once they felt their vision had improved. The treatment also facilitated resuming their recreational and social activities thus favoring integration, but in other cases visual impairment kept limiting their participation. In this sense the conditions of the context, family assistance and social networks influenced the way in which patients faced the disease and its treatment, modifying their perception of autonomy. In certain cases, clinical improvement did not turn into full functional recovery, which is why it was necessary to continue receiving assistance in their everyday life. Still, a few patients manifested their gratitude with their healthcare team, thanks to their perceived improvement and the independency gained, which in turn had a positive impact vis-à-vis treatment adherence and reflecting more self-confidence and greater QoL. To sum up, the findings show that QoL is influenced by the interaction of timely access to treatment, social inclusion and the multiple wellbeing dimensions. Even though access to treatment raised concerns and fear for the potential failure of the system and associated costs, it was also recognized as a pillar for their respectful care and care continuity. Family support and community networks served to protect the patients from isolation, although visual impairment and perceived stigma limited social participation in certain cases. The emotional process was initially characterized by fear and uncertainty, evolving into greater adaptation and hope, especially when there was assistance, trust in the healthcare team, and in some cases, spiritual aid. However, access barriers, insufficient information and difficulties in providing care continue to represent risks to adherence and QoL, which makes evident the need to reinforce strategies focused on the patients and their surroundings. The findings of this study should be interpreted in light of several considerations. This qualitative study was conducted at a single ophthalmological center using a small purposive sample of patients receiving intravitreal aflibercept, which may limit the transferability of the findings beyond the Colombian setting. Participants’ perceptions may have been influenced by factors such as disease stage, age, productive life stage, and health insurance coverage; however, the study was designed to explore patients’ experiences rather than identify factors associated with these perceptions. Telephone interviews may have introduced recall and social desirability bias, while participants’ perceptions of treatment may have been influenced by the treating institution. In addition, caregiver perspectives were not included, and participants’ accounts were not triangulated with objective clinical measures such as visual acuity or optical coherence tomography. Future studies should further explore the individual, clinical, and healthcare-related factors that shape patients’ experiences and QoL. Conclusion Among patients with neovascular age-related macular degeneration receiving intravitreal aflibercept, quality of life was described as a multidimensional experience shaped by fear of visual loss, anxiety related to repeated injections, perceived changes in functional independence, family and community support, trust in the ophthalmologist, transportation difficulties, and concerns about sustained access to treatment (Figure 1). Although several participants associated therapy with visual stability, hope, and the ability to maintain daily and social activities, others continued to report dependence, mobility limitations, financial burdens, and uncertainty regarding treatment continuity. These findings support the incorporation of comprehensive pretreatment counseling, strategies to identify and manage injection-related anxiety, transportation assistance, active caregiver involvement, and coordinated measures to ensure uninterrupted access to anti-VEGF therapy as part of patient-centered care. Conceptual framework illustrating the relationships among emotional wellbeing, functional independence, social support, healthcare access, and treatment adherence in patients with neovascular age-related macular degeneration receiving intravitreal aflibercept. The framework was developed from the qualitative findings and informed by the Felce and Perry multidimensional quality-of-life model. Funding Statement The authors would like to thank the Vice Presidency of Research & Creation’s Publication Fund at Universidad de los Andes for its financial support. The authors would like to thank the Vice Presidency of Research at Universidad El Bosque for its financial support. Artificial Intelligence (AI) Use Disclosure AI-assisted tools were used in limited aspects of this research. ATLAS.ti vs.26 software, which incorporates AI-supported functions, was used to assist with interview transcription and qualitative data organization. OpenAI ChatGPT 5.5 was used briefly to support language refinement and drafting assistance in the Introduction section only. In addition, the conceptual framework presented in Figure 1 was developed by the authors, including its structure, themes, and relationships, while the graphical illustration was generated with AI (ChatGPT 5.6 SoL) based on the authors’ specifications. AI tools were not used for data analysis, interview interpretation, generation of results, or formulation of conclusions. All analytical interpretation, figure content, and final manuscript content were conducted, reviewed, and approved exclusively by the authors. Abbreviations AMD, Age-Related Macular Degeneration; VEGF, Vascular Endothelial Growth Factor; QoL, Quality of Life; WHO, World Health Organization; CIE, Institucional Board; SD, Standard Deviation; OCT, Optical Coherence Tomography; AI, Artificial Intelligence. Ethics Approval This study was conducted in accordance with the principles of the Declaration of Helsinki and approved by the Institutional Board of Ethics of Universidad El Bosque (project code CIE 2025-018). All participants provided written informed consent prior to inclusion in the study, including consent for the publication of anonymized responses and direct quotations. The study was conducted in compliance with established ethical principles, ensuring the confidentiality, autonomy, and rights of all participants. Disclosure The authors report no conflicts of interest in this work. References